1.77

2.91% 0.05

Maravai Lifesciences Holdings Inc (MRVI)

Overview News Price History Option Chain Financials Why MRVI Down? Discussions Forecast

Maravai Lifesciences Holdings Inc stock is traded at $1.77, with a volume of 2.24M. It is up +2.91% in the last 24 hours and down -32.95% over the past month. Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Previous Close:

$1.72

Open:

$1.69

24h Volume:

2.24M

Relative Volume:

0.70

Market Cap:

$254.26M

Revenue:

$288.95M

Net Income/Loss:

$-119.03M

P/E Ratio:

-1.9656

EPS:

-0.9005

Net Cash Flow:

$60.67M

1W Performance:

-0.56%

1M Performance:

-32.95%

6M Performance:

-78.18%

1Y Performance:

-77.10%

1-Day Range:

$1.665

$1.79

1-Week Range:

$1.665

$1.89

52-Week Range:

$1.665

$11.55

Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile

Name

Maravai Lifesciences Holdings Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

(858) 546-0004

Address

10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO

Employee

570

Twitter

Next Earnings Date

2025-03-18

Latest SEC Filings

MRVI's Discussions on Twitter

Compare MRVI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MRVI Maravai Lifesciences Holdings Inc	1.77	254.26M	288.95M	-119.03M	60.67M	-0.9005
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-26-25	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-19-24	Initiated	Guggenheim	Neutral
Dec-05-24	Downgrade	Goldman	Neutral → Sell
Nov-14-24	Initiated	Wolfe Research	Peer Perform
Nov-08-24	Downgrade	William Blair	Outperform → Mkt Perform
Aug-28-24	Initiated	Wells Fargo	Overweight
Aug-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-10-24	Initiated	Craig Hallum	Buy
Dec-12-23	Upgrade	BofA Securities	Neutral → Buy
Aug-08-23	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
May-23-23	Downgrade	Credit Suisse	Outperform → Neutral
May-09-23	Downgrade	Goldman	Buy → Neutral
Jan-05-23	Downgrade	UBS	Buy → Neutral
Dec-14-22	Initiated	Deutsche Bank	Buy
Dec-07-22	Initiated	RBC Capital Mkts	Outperform
Nov-03-22	Downgrade	BofA Securities	Buy → Neutral
Aug-25-22	Initiated	Credit Suisse	Outperform
Aug-05-21	Resumed	Credit Suisse	Outperform
Dec-16-20	Initiated	KeyBanc Capital Markets	Overweight
Dec-15-20	Initiated	BofA Securities	Buy
Dec-15-20	Initiated	Credit Suisse	Outperform
Dec-15-20	Initiated	Goldman	Buy
Dec-15-20	Initiated	Jefferies	Buy
Dec-15-20	Initiated	Robert W. Baird	Outperform
Dec-15-20	Initiated	Stifel	Buy
Dec-15-20	Initiated	William Blair	Outperform
Dec-14-20	Initiated	UBS	Buy

View All

Maravai Lifesciences Holdings Inc Stock (MRVI) Latest News

Apr 19, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 19, 2025

Apr 18, 2025

2025-04-18 | Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2025 in Maravai LifeSciences Holdings, Inc. LawsuitMRVI | NDAQ:MRVI | Press Release - Stockhouse

Apr 18, 2025

Maravai LifeSciences (MRVI) Reports Weak Q4, Faces Investor Class Action – Hagens Berman - TradingView

Apr 18, 2025

Maravai LifeSciences (MRVI) Reports Weak Q4, Faces Investor Class Action – Hagens Berman - GlobeNewswire Inc.

Apr 18, 2025

DEADLINE ALERT for SWKS, MRVI, APP, and RC: The Law Offices - GlobeNewswire

Apr 18, 2025

Deadline Alert: Maravai LifeSciences Holdings, Inc. (MRVI) - GlobeNewswire

Apr 18, 2025

2025-04-18 | Faruqi & Faruqi Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025MRVI | NDAQ:MRVI | Press Release - Stockhouse

Apr 18, 2025

Levi & Korsinsky Notifies Maravai LifeSciences Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineMRVI - PR Newswire

Apr 18, 2025

Apr 17, 2025

ROSEN, A LEADING LAW FIRM, Encourages Maravai Lifesciences Holdings, Inc. Investors to Secure - Bluefield Daily Telegraph

Apr 17, 2025

Maravai LifeSciences (MRVI) Reports Weak Q4, Faces Investor Class ActionHagens Berman - TradingView

Apr 17, 2025

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire

Apr 17, 2025

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2025 in Maravai LifeSciences Holdings, Inc. Lawsuit – MRVI - TradingView

Apr 17, 2025

Maravai LifeSciences Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before May 5, 2025 to Discuss Your RightsMRVI - MarketScreener

Apr 17, 2025

Apr 16, 2025

Kirby McInerney LLP Urges Investors in Maravai Lifesciences Holdings, Inc. to Inquire About Their Rights in Class Action Lawsuit - Business Wire

Apr 16, 2025

Maravai LifeSciences (MRVI) Earnings Call Raises Questions Amid Legal Allegations – Hagens Berman - GlobeNewswire

Apr 16, 2025

MRVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Apr 16, 2025